ISCO.OB will present data on its progress toward producing human liver cells from immune-matched patient-specific parthenogenetic stem cells at The Liver Meeting®, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (ASSLD), in Boston, MA from 11/29 – 11/2, 2010.
- ISCO uses unfertilized eggs (oocytes) to create human “parthenogenetic” stem cells (hpSCs);
- Like human embryonic stem cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to become almost any cell type in the body, yet avoid ethical issues associated with use or destruction of viable human embryos;
- Unlike hESCs, hpSCs can be created in a form such that they can be immunologically matched to millions of individuals;
- This makes possible, for the first time, the establishment of a bank containing a manageable number of stem cell lines immune matched to a large patient population.
ISCO will present a new method of obtaining highly enriched cultures of differentiated cells from pluripotent human stem cells, based on a natural physiological process. Also a follow-on presentation will demonstrate that differentiation protocols previously developed for human embryonic stem cells can, with some modification, be effectively applied to human parthenogenetic stem cells.
- These findings will be presented as part of the “Stem Cell Poster Session” on 11/1/10, and are entitled, “Hepatocyte-like cells derived from patient-specific human parthenogenetic stem cells possess functions of mature human hepatocytes including P450 activity” and, “Derivation of highly enriched populations of hepatocytes from various types of human pluripotent stem cells using a novel physiological method.”
In addition, ISCO announced 10/7/10, the signing of an agreement with Explora BioLabs, a leading California-based CRO specializing in conducting high-quality pre-clinical in vivo studies